

430 Rec'd PCT/PTO 07 SEP 1999

FORM PCT-1990 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PC9835AJTJ
TRANSMITTAL LETTER TO THE UNITED STATES PATENT AND TRADEMARK OFFICE DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (Automatic, see 35 C.F.R. 1.5) Not yet assigned 09/380825
INTERNATIONAL APPLICATION NO. 98/00933	INTERNATIONAL FILING DATE June 15, 1998 (06.15.1998)	PRIORITY DATE CLAIMED July 1, 1997 (07.01.1997)
TITLE OF INVENTION SOLUBILIZED SERTRALINE COMPOSITIONS		
APPLICANT(S) FOR DO/EO/US Dwayne Thomas FRIESEN, Scott Max HERBIG, Ravi Mysore SHANKAR, and James Blair WEST		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is the FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is the SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. To 16. Below concern other documents(s) or information included:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ol style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information: 		

EXPRESS MAIL NO. 9324820657905

U.S. APPLICATION NO. 097380825 Not yet assigned		INTERNATIONAL APPLICATION NO PCT/IB98/00933		ATTORNEY'S DOCKET NUMBER PC9835A	
17. <input checked="" type="checkbox"/> The following fees are submitted BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): <input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO\$840.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37CFR 1.482)\$670.00 <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$760.00 <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$970.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$ 96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY \$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	29 - 20 =	9	X \$ 18.00	\$162.00	
Independent Claims*	4 - 3 =	1	X \$ 78.00	\$78.00	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,080.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note: 37 CFR 1.9, 1.27, 1.28)				\$	
SUBTOTAL =				\$1,080.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1,080.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$1080	
				Amount to be Refunded	\$
				Charged	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 16-1445 in the amount of \$ <u>1,080.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.16-1445. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Gregg C. Benson Pfizer Inc Eastern Point Road, Groton, CT 06340					
				Signature <u>James T. Jones</u> James T. Jones Name 30,561 Registration Number	

09/380825

514 Rec'd PCT/PTO 07 SEP 1999

PATENT

PC9835AJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Dwayne Thomas Friesen, et al.

SERIAL NO.: To Be Assigned	:	Examiner: To Be Assigned
	:	Art Unit: To Be Assigned

FILED: Herewith

FOR: Solubilized Sertraline Compositions

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please make the following changes to the application:

In the specification:

Please enter the following sentence as the first paragraph following the title:


--This is a National Stage filing under 35 USC §371 based on PCT/IB98/00933, which was filed internationally on June 15, 1998 and which claims priority from US provisional applications 60/051,413 filed July 1, 1997.--

Remarks

The above sentence has been entered to update the status of this application as a National Stage entry under the Patent Cooperation Treaty and so that, in accordance with 35 USC §120, the application contains a specific reference to the US provisional applications from which priority has been claimed.

Respectfully Submitted,

Date: SEP. 7, 1999


James T. Jones
Attorney for Applicants
Reg. No. 30,561

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, Connecticut 06340
860-441-4903

EXPRESS MAIL NO. 85248206579US

09380825-000799

Solubilized Sertraline CompositionsField of the Invention

This invention relates to a composition comprising sertraline or a pharmaceutically acceptable salt thereof and a solubilizing agent which prevents gel formation or otherwise maintains the solubility of sertraline in a use environment containing chloride ions. The invention further relates to a method of treating a psychiatric or other illness comprising administering sertraline in such a solubilized composition to a mammal, including a human patient, in need of such treatment.

Background of the Invention

Sertraline is a selective serotonin reuptake inhibitor (SSRI), which is useful as an antidepressant and anorectic agent, and in the treatment of obsessive-compulsive disorder, premenstrual dysphoric disorder, post-traumatic stress disorder, chemical dependencies, anxiety-related disorders, panic and premature ejaculation.

Sertraline is most commonly prescribed for therapy of depressive illness, in the general dose range 50-200 mg/day. Sertraline has an elimination half-life of 23 hr and is dosed once daily. Commercially, sertraline is available as the hydrochloride salt which is undeniably therapeutically effective, many patients having availed themselves of the benefits of this drug.

Some forms of sertraline, particularly salts which exhibit high solubility, can be problematic, however. Such salts, generally those having an aqueous solubility in excess of 10 mg/mL, can exhibit a tendency to form a gel and/or exhibit reduced solubility (e.g., precipitate as a salt or as the free base having a lower solubility in the environment of use than the salt form originally administered) when exposed to a use environment containing chloride ions such as the gastrointestinal tract. The gel itself tends to dissolve slowly and otherwise releases sertraline at a slow rate, thereby affecting absorption. It is not known whether gelation is the only mechanism which impacts the solubility of sertraline in a use environment. However, therapeutic difficulties can accordingly arise from administering an immediate-release dosage form *in vivo* if solubility is affected, regardless of mechanism. Problems can similarly arise in the case of controlled-release dosage forms since the controlled release profile of the dosage form can be altered *in vivo* by factors affecting solubility. The

- unanticipated phenomenon of gelation of sertraline salts in a chloride ion-containing environment can thus create therapeutic difficulties by unexpectedly altering the release profile of a dosage form, whether immediate-release or controlled-release. The mechanism of sertraline gelation is not well understood, and can be all the more
- 5 problematic therapeutically since the release characteristics of a gel formed *in situ* may not be anticipated.

- In particular, gelling of sertraline in sustained-release dosage forms can be detrimental in those sustained release systems known as non-eroding matrix systems, reservoir systems, and osmotic systems. In each of these types of
- 10 sustained release formulations release of the drug is dependent on transport of the drug across a distance within the device (matrix or coating layer) to the surrounding fluid. This drug transport can occur by diffusive or convective mechanisms. In both mechanisms, formation of a gel can reduce transport by an order of magnitude or more and in some cases can result in devices that exhibit incomplete drug release
- 15 (e.g., less than 70% of the total drug in the formulation).

Summary Of The Invention

- This invention provides a composition of matter, suitable for administration to a mammal, including a human, comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of an excipient, herein termed a "solubilizing agent" sufficient to effect a concentration of dissolved sertraline in a use environment
- 20 containing chloride ions which is at least 1.5 times higher, preferably 2 times higher, more preferably 3 times higher than the concentration effected by a comparative composition of matter (i.e., a control) identical thereto but for the inclusion of said solubilizing agent. The use environments mainly intended are the aqueous *in vivo*
- 25 digestive fluids of the gastrointestinal (GI) tract including the stomach, small intestine and large intestine, and aqueous *in vitro* chloride ion-containing test media, as further described below. The compositions are suitable for formulating into oral dosage forms including tablets, capsules, multiparticulates, powders for oral suspension, and unit dose packets (sometimes referred to in the art as a "sachet"). In addition the
- 30 compositions can be used in liquid dosage forms such as oral solutions or suspensions and injectable formulations. For making the compositions of this invention into oral dosage forms, conventional techniques known to the art can be

employed. The composition can additionally comprise other conventional pharmaceutical ingredients and/or a pharmaceutically acceptable carrier.

By this invention, it has been determined that in cases of dosage forms containing sertraline salts which form gels or which otherwise exhibit reduced solubility in a use environment, solubility may advantageously be increased, and in some cases solution viscosity may be advantageously decreased, by employing the sertraline salt together with a solubilizing agent which increases the sertraline's solubility. The solubilizing agent preferably also maintains solubility, meaning that the level of dissolved sertraline in a use environment, regardless of the salt employed, is held at a concentration greater than or equal to 1.5 times the concentration of sertraline in a like formulation without solubilizing excipient, for at least 2 hours. For many dosage forms it may be advantageous to maintain the sertraline concentration greater than or equal to 1.5 times the concentration of sertraline in like formulations without solubilizing excipient for longer periods of time such as 4 hours, 8 hours, 16 hours, or 20 hours, and this can be effected by the choice and amount of solubilizing agent. It has otherwise been determined that in a chloride ion-containing use environment without a solubilizing agent, for example a test environment such as 0.075M sodium chloride solution, sertraline solubility is generally less than 10 mgA/mL, usually less than 5 mgA/mL, regardless of the salt employed, and despite the fact that many of the salts themselves exhibit solubilities in pure water (i.e., no chloride ions) well in excess of 10 mgA/mL. Solubilizing agents thus could also be construed to be compounds that maintain sertraline concentrations of 10mgA/ml or greater in chloride-ion-containing environments of use.

Reference herein to "a solubilizing agent" herein, including the claims, shall be understood as also including the use of more than one solubilizing agent in a composition, added separately or as a mixture.

As mentioned above, the term "use environment" can refer to the aqueous *in vivo* chloride ion-containing digestive fluids of the stomach, or to an *in vitro* chloride ion-containing aqueous environment used to test a dosage form for its sertraline release characteristics. A useful *in vitro* test environment for purposes of this invention is 0.075M sodium chloride. 0.075M sodium chloride is preferred as a test medium because of its ready availability and similar chloride ion concentration to the

lower levels of chloride ions found in the fluids in the GI tract. Blood & Other Body Fluids, Dorothy S. Dittmer, ed., Federation of American Societies for Experimental Biology, Washington, D.C., 1961, pp. 404-419. Thus, as an additional feature, this invention provides an *in vitro* test to determine whether a dosage form is within the

5 scope of the invention. That is, the invention provides a composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a solubilizing agent sufficient to produce and to maintain, for at least 2 hours in 0.075M sodium chloride, a concentration of dissolved sertraline which is at least 1.5 times higher than the concentration effected by a comparative composition of matter

10 identical thereto but for the inclusion of said solubilizing agent. Agitation should be employed during the test although, as explained below, the degree or type of agitation is not critical. Salt solution temperature is not believed to be particularly critical so long as it is about 37°C, plus or minus 3°C, throughout the test. Excipients, including the solubilizing agent(s) should be at the desired concentration in the

15 aqueous test solution prior to adding sertraline and sodium chloride. Sertraline is then added to a concentration ranging between 80% to 100% of its saturation concentration in the test solution. This solution should be decanted off or filtered away from any solids. To this solution a 3M NaCl solution is slowly added with stirring until the NaCl concentration in the test solution is 0.075M. The sertraline

20 concentration in this test solution after 2 hours is compared with a control solution made in the same manner and consisting of the same components except the solubilizing agent.

Alternatively, a solubilizing excipient can be identified in an *in vivo* test such as a crossover study. In an *in vivo* crossover study a solubilized sertraline-

25 containing dosage form is dosed to half a group of 12 or more humans and, after an appropriate washout period (e.g., one week) the same subjects are dosed with a dosage form otherwise identical but for inclusion of the solubilizing agent. The other half of the group is dosed with the non-solubilized dosage form first, followed by the solubilized dosage form. Maximum concentration in the blood (C_{max}) and/or

30 bioavailability, measured as the area under the curve (AUC) for a plot of the concentration of sertraline in blood versus time, is determined for each group. By comparison, assessment of the solubilized dosage form can be made. If the average

- C_{\max} or AUC for the formulation containing the solubilizing agent is greater by 10% or more than the formulation without the solubilizing agent, then the solubilizing excipient is an embodiment of this invention. It is preferred that the C_{\max} and/or AUC be greater by at least 15%, and more preferred either or both be greater by at least 20%.
- 5 The determination of AUC's is a well known procedure and is described, for example, in "Pharmacokinetics; Processes and Mathematics," by Peter Welling (ACS Monograph 185, Amer. Chem. Soc., Wash. D. C., 1986). Thus, as an additional feature of the invention, the invention provides a composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a
- 10 solubilizing agent sufficient to effect, *in vivo*, a C_{\max} and/or an AUC which is greater by at least 10% than the C_{\max} and/or AUC effected by a comparison composition of matter (i.e., a control) identical thereto but for the inclusion of said solubilizing agent.

- The invention further provides a method of increasing the solubility of sertraline in an aqueous chloride ion-containing environment, comprising
- 15 administering said sertraline in a composition of matter comprising sertraline and a solubilizing agent.

- The invention is surprising in that, prior to the invention, it was not known that (1) the phenomenon of reduced sertraline solubility in chloride ion-containing environments existed, nor that (2) any chemical agent existed which would reduce or
- 20 prevent sertraline gelation or reduced sertraline solubility in chloride ion-containing use environments or otherwise operate to increase sertraline's solubility in such use environments. The term "solubilized sertraline" is used herein to refer to a composition comprising sertraline or a sertraline salt plus an excipient (i.e. the solubilizing agent) which prevents gelation or otherwise increases, and preferably
- 25 maintains, the solubility of the sertraline salt in an *in vivo* or *in vitro* chloride ion-containing use environment. Likewise, the term "solubilize" is used to denote that the solubility of a sertraline salt is being increased by at least 1.5 times in a use environment over what it would be in the absence of a solubilizing agent.

- The invention is preferred for use with the aspartate, acetate, and lactate salts
- 30 which are salts that exhibit high solubilities in water relative to the free base. These salts are disclosed in commonly assigned co-pending application PC9337JTJ, filed

as a PCT application designating the United States, and herein incorporated by reference.

For convenience and consistency, reference to "sertraline" in terms of therapeutic amounts herein, including the claims, is to active sertraline, abbreviated herein as "mgA", i.e., the non-salt, non-hydrated free base having a molecular weight of 306.2. Amounts in mgA can conveniently be converted to equivalent weights for whatever salt form is desired.

Many solubilizing agents useful herein can be grouped into several broad categories:

10

15

20

1. Organic acids and organic acid salts;
2. Partial Glycerides, i.e., less than fully esterified derivatives of glycerin, including monoglycerides and diglycerides;
3. Glycerides;
4. Glyceride derivatives;
5. Polyethylene glycol esters;
6. Polypropylene glycol esters;
7. Polyhydric alcohol esters;
8. Polyoxyethylene ethers;
9. Sorbitan esters; and
10. Polyoxyethylene sorbitan esters.
11. Carbonate salts

Detailed Description

The amount of solubilizing agent employed in a composition according to the invention depends on the particular solubilizing agent employed.

In the case of solubilizing agents which are organic acids the preferred amount of solubilizer can be calculated as a ratio multiplied by the quantity of sertraline to be used, wherein the ratio is of organic acid solubility to solubility of sertraline salt:

30

$$(\text{organic acid or salt solubility/sertraline or sertraline salt solubility}) \times \text{quantity of sertraline}$$

where the solubilities referred to are in mg/ml. The above expression is approximate, and some adjustment may be advantageous for optimization. Generally the above expression will give a quantity which is plus or minus 25% of the final value

- 5 employed, although higher quantities of solubilizing agent can be incorporated without any particular additional advantage. In addition, organic acid salts can be added to modify the pH and/or solubility of the organic acid, effectively optimizing the solubilization effect of the agents.

- For other types of solubilizing agents listed, typically the amount of solubilizing agent employed in the dosage form will be 1 to 150% by weight of the amount of sertraline employed therein, preferably 1 to 100%, more preferably 3 to 75%. Amounts of solubilizing agent higher than 150% may be employed, although it is believed that in most cases no particular advantage would be provided.
- 10

- Salts of sertraline or excipients that in combination with sertraline aid in solubilizing sertraline can be beneficial to virtually any type of sertraline dosage forms intended for oral administration, including immediate release as well as controlled release systems, including (1) sustained-release dosage forms which meter out sertraline as they progress through the gastrointestinal system and (2) delayed release systems which release sertraline after an initial delay period following
- 15 ingestion. Immediate-release systems are well known and commercially available in both solid and liquid formulations. Controlled release dosage forms of sertraline are discussed and disclosed in commonly assigned co-pending applications Pfizer Docket PC9337JTJ and PC9824JTJ, each of which is a PCT application designating the United States and each herein incorporated by reference in its entirety.
- 20
- 25 Solubilized sertraline can enhance release from the dosage form by increasing the concentration gradient for diffusive based systems such as matrix dosage forms and reservoir dosage forms. Solubilized sertraline can also enhance delivery from osmotic dosage forms in that a more soluble sertraline can increase the osmotic pressure in the core and increase the sertraline concentration in the fluid that is pumped or extruded out of the dosage form. In addition, solubilized sertraline can
- 30 benefit sustained-release formulations by aiding absorption of drug from the G.I.

tract. For example, higher concentrations of drug in the colon can increase absorption due to a higher concentration gradient across the intestinal wall.

It is noted that currently available commercial dosage forms of sertraline are immediate-release dosage forms containing sertraline hydrochloride. Even though
5 the hydrochloride has proven to be very effective, it is possible that dosage forms containing the hydrochloride can also benefit by the addition of a solubilizing agent.

Examples of organic acids useful in the invention include malic, citric, erythorbic, adipic, glutamic, aspartic, maleic, aconitic, and ascorbic acid. Preferred acids are citric, erythorbic, ascorbic, glutamic, and aspartic. Salts of organic acids
10 such as alkalkine earth metal (magnesium, calcium) salts and alkali metal (lithium, potassium, sodium) salts are also effective as well as mixtures of organic acids and their salts. Calcium salts such as calcium carbonate, calcium acetate, calcium ascorbate, calcium citrate, calcium gluconate monohydrate, calcium lactobionate, calcium gluceptate, calcium levulinate, calcium pantothenate, calcium propionate,
15 calcium phosphate dibasic, and calcium saccharate are preferred organic acid salts.

Examples of compounds within the other categories mentioned above are summarized in Table 1.

Table 1

Solubilizing Agents

Class	Examples, Chemical Name	Examples, Trade Designation, (Vendor)
Partial Glycerides	Glyceryl Monocaprylate	Monocaprylin [®] (Sigma), Capmul [®] MCM(Abitec), Imwitor [®] 308 (Hüls)
	C8-C10 Partial Glycerides	Capmul [®] MCM (Abitec), Imwitor [®] 742 (Hüls), Imwitor [®] 988 (Hüls)
	Glyceryl Monooleate	Myverol [®] 18-99 (Eastman), Calgene [®] GMO (Calgene), Capmul [®] GMO(Abitec)
	Glyceryl Monolinoleate	Myverol [®] 18-92 (Eastman)
	Glyceryl Monostearate	Imwitor [®] 191 (Hüls) Calgene [®] GSO(Calgene)
	Glycerol Monolaurate	Imwitor [®] 312 (Hüls) Calgene [®] GLO (Calgene)
	Glyceryl Dilaurate	Capmul [®] GDL (Abitec)
Glycerides	Triacetin	Triacetin (Sigma)
Glyceride Derivatives	PEG-Derivatized Glycerides	Cremophor [®] RH40, Cremophor [®] RH60 (BASF), Acconon CA5, CA-9, CA-15, W230, TGH (Abitec)
	Polyglycolized Glycerides	Gelucire [®] 44/14, 42/12, 50/13, 53/10, 35/10, 48/09, 46/07, 62/05, 50/02; Labrasol [®] (Gattefosse); Capmul [®] 3GO; 3GS, 6G2O, 6G2S, 10G4O, 10G100 (Abitec)
Polyethylene glycol Esters	PEG 200 Monolaurate, PEG 400 Monolaurate, PEG 600 Monolaurate	Calgene [®] 20-L, Calgene [®] 40-L, Calgene [®] 60-L
	PEG 200 Monostearate, PEG 400 Monostearate, PEG 600 Monostearate	Calgene [®] 20-S, Calgene [®] 40-S, Calgene [®] 60-S
	PEG 200 Dilaurate, PEG 400 Dilaurate, PEG 600 Dilaurate	Calgene [®] 22-L, Calgene [®] 42-L, Calgene [®] 62-L
Polypropylene Glycol Esters	Propylene Glycol Dicaprylate	Captex [®] 200 (Abitec)
Polyhydric Alcohol Esters	Diethylene Glycol Monolaurate	Calgene [®] DGL

00380025.000709

	Propylene Glycol Monolaurate	Calgene® PGML
	Ascorbyl Palmitate	Ascorbyl Palmitate (Sigma)
Polyoxyethylene Ethers	PEG Lauryl Ether	Nonionic L-4 (Calgene)
	PEG Stearyl Ether	Nonionic S-20 (Calgene), Myrj 45, 52, 53, 59 (Sigma)
Sorbitan Esters	Sorbitan Monolaurate	Calgene® SML, Span® 20 (Sigma)
	Sorbitan Monooleate	Calgene® SMO, Span® 80 (Sigma)
Polyoxyethylene Sorbitan Esters	POE-20 Sorbitan Monolaurate	Calgene® PSML-20, Span® 20(Sigma), Tween 20 (Sigma), Capmul® POE-L (Abitec)
	POE-20 Monooleate	Tween® 80, PSMO-20
Saccharide Esters	Sucrose Monolaurate	Ryoto LW-1540 (Chem Service)
Phospholipids	Phosphatidyl choline	Lecithin (Sigma)
	Mixed phospholipids	Emphos D70-30C (Witco)
Block Co-polymers	PEO-PPO Block Copolymers	Pluronic® F-68, F127, L-62 (BASF)
Polyethylene Glycols	PEG 3350	Various sources

In addition other compounds useful as solubilizing agents in the invention are ethyl propionate, methyl paraben, propyl paraben, propyl gallate, niacinamide, ethyl vanillin, paraaminobenzoic acid, butylated hydroxyanisole, imidurea, and glycine. It is also noted that preferred compositions include mixtures of an organic acid with or without a corresponding organic acid salt, and one or more of the non-organic solubilizers listed above or in Table 1. It is also noted that it has generally been observed that in order to be most effective the solubilizer should have a solubility in the aqueous chloride-ion containing use environment of at least 1mg/ml, and

preferably greater than 5mg/ml.

A preferred group of solubilizing agents, in addition to the preferred organic acids previously mentioned, includes those in Table 2.

Table 2

Preferred Solubilizing Agents

Class	Examples, Chemical Name	Examples, Trade Names (source)
Partial Glycerides	Glyceryl monocaprylate	Monocaprylin [®] (sigma), Capmul [®] MCM(Abitec), Imwitor [®] 308 (Hüls)
	C8-C10 Partial Glycerides	Capmul [®] MCM (Abitec), Imwitor [®] 742 (Hüls), Imwitor [®] 988 (Hüls)
	Glyceryl Monostearate	Imwitor [®] 191 (Hüls) Calgene [®] GSO(Calgene)
	Glyceryl Monolaurate	Imwitor [®] 312 (Hüls) Calgene [®] GLO (Calgene)
Glycerides	Triacetin	Triacetin [®] (Sigma)
Sorbitan Esters	Sorbitan Monolaurate	Calgene [®] SML, Span [®] 20 (Sigma)
	Sorbitan Monooleate	Calgene [®] SMO, Span [®] 80 (Sigma)
Phospholipids	Phosphatidyl choline	Lecithin [®] (Sigma)
	Mixed phospholipids	Emphos D70-30C (Witco)
Block Co-polymers	PEO-PPO Block Copolymers	Pluronic [®] F-68, F127, L-62 (BASF)
Polyethylene Glycols	PEG 3350	Various sources

5

Note: Commercial vendors shown above are as follows:

Abitec Corp. Janesville, WI

BASF, Parsippany, NJ

Calgene Chemical Inc. Skokie, IL

10 Chem Service, Inc., West Chester, PA

Hüls America, Piscataway, NJ

Sigma, St. Louis, MO

Witco, Houston, TX

Preferred combinations of solubilizing agents include (1) an organic acid plus a salt of the same or a different organic acid, (2) an organic acid plus a non-ionic solubilizing agent such as any of those listed in Table 1, and (3) an organic acid plus a salt of the same or a different organic acid plus a non-ionic solubilizing agent.

- 5 Particularly preferred individual solubilizing agents include aspartic acid, glyceryl monocaprylate, glyceryl monolaurate, calcium acetate, ascorbic acid, citric acid, glutamic acid, and calcium carbonate. Aspartic acid, glyceryl monocaprylate, glyceryl monolaurate and calcium acetate are most preferred.

- As previously discussed, a dosage form can be tested *in vitro* to determine
10 whether an excipient has a solubilizing effect on sertraline in a chloride-ion containing use environment and thus is useful as a solubilizing agent. A 0.075M NaCl solution is preferred for use as a test medium although other chloride-ion containing solutions with equivalent or higher chloride ion concentration than 0.075M (e.g., 0.1N HCl or isotonic saline) may be used to determine the solubilizing effect of a test excipient. In
15 some cases reduced solubility is evident simply by adding a dosage form such as a powder to the test medium because gelation is visible. Similar problems may be evident in a dosage form such as a tablet if the tablet is, for example, cut open and gelation is visible on its open face. A recommended procedure is to initially make a solution containing the desired excipients, including solubilizing agent(s). The
20 excipients can be at any concentration relevant to the intended dosage form, but are typically for organic acids and soluble salts or sugars 80-100% of saturation. For other surfactant-like compounds, concentrations typically range from 1 to 150% of the sertraline concentration in the test solution. Sertraline is added to this excipient-containing solution at a concentration typically 80-100% of saturation. The solution is
25 filtered or decanted to remove any solids and then a 3M solution of sodium chloride is added until the sodium chloride concentration is 0.075M. The concentrated sodium chloride solution should be added dropwise with stirring. This test medium should be kept at a temperature on the order of 37°C for at least 2 hours at which time the sertraline concentration in solution is determined. It is preferred that the sertraline
30 concentration be maintained for 4 hours, more preferably for 8 hours, still more preferably for 16 hours, and most preferably for at least 20 hours. The amount of agitation is not critical. When sampling the test medium, filtration or centrifugation

can be employed to obtain solution that is free of any solids or gel material, and also to avoid inclusion of particulates (which may contain sertraline) in the sample.

Analysis of the samples to determine sertraline concentration can be accomplished via several conventional analytical methods, such as by high performance liquid

- 5 chromatography (HPLC). For example, sertraline concentrations can be determined using reverse phase HPLC with a ULTRACARB® 5 ODS 4.6 x 250 mm column (Phenomenex, Torrance, CA), and a mixture of acetic acid, triethylamine, acetonitrile, and water as mobile phase, with UV detection at 230 nm. For example, the mobile phase can be prepared by combining, with stirring, 2.86 ml of glacial acetic acid, 3.48
- 10 ml of triethylamine, diluting to a liter with water, and filtering and degassing. Flow rates are typically on the order of 1.5 ml/min, and retention times about 4 minutes.

- Dosage forms with solubilizing agent can be formulated by conventional techniques. Immediate release dosage forms can be capsules, tablets, multiparticulates, liquid solutions or suspensions. Capsule formulations can be either soft
- 15 gelatin capsules where the sertraline is either dissolved or suspended within the capsule core or hard gelatin capsules filled with multiparticulates, tablets or a liquid (solution or suspension) fill. Immediate release tablets can be by techniques standard in the industry by simply including the solubilizing agent as one or more of the tablet excipients. Likewise immediate-release multiparticulates can be made that
- 20 include solubilizing agents by techniques such as extension spheronization, rotary granulation, coating seed cores or other methods common in the pharmaceutical industry. Liquid formulations consisting of a solution or suspension or both can be made by methods common in the pharmaceutical industry.

- Controlled-release dosage forms can also be made that include solubilizing
- 25 agents by methods common in the pharmaceutical industry. Controlled release dosage forms include a wide variety of dosage forms that impart control over the dissolution rate or rate of release of sertraline from the dosage form. Such dosage forms include but are not limited to sustained release, delayed and then immediate release, delayed and then sustained release and a dosage form with a small portion
- 30 of sertraline released immediately and then followed by the majority of the sertraline in the dosage release at a sustained rate. Other algorithms of release can also be

attained such as pulsatile release. Many such formulations are described in aforementioned co-pending applications PC9337JTJ and PC9824JTJ.

Standard techniques can be used to make controlled release dosage forms. For example, tablets can be made by commonly used direct compression methods

5 that contain sertraline and a solubilizing agent. To provide delayed release, a pH-sensitive coating can be applied to these tablets via a side-vented pan coater (e.g., HCT-60 tablet coater, Vector Corp.). The pH sensitive coating is resistant to low pH environments such as typically in the stomach and then dissolves, releasing sertraline, in neutral pH environment such as typically in the small intestine. Such

10 coating materials (e.g., cellulose acetate phthalate or methacrylic acid copolymer) are common in the pharmaceutical industry. Alternatively, the tablets can be coated with a porous or semipermeable membrane coating to provide sustained release of the tablet cores. A particularly useful process for applying a membrane coating comprises dissolving the coating polymer in a mixture of solvents chosen such that

15 as the coating dries, a phase inversion takes place in the applied coating solution, resulting in a membrane with a porous structure. Numerous examples of this type of coating system are given in European Patent Specification 0 357 369 B1, published March 7, 1990, herein incorporated by reference. Many other types of controlled release dosage forms can also be made that benefit from the inclusion of solubilizing

20 agents such as matrix systems which include but are not limited to 1) non-eroding matrices, tablets, multiparticulates and hydrogel-based systems; 2) hydrophilic eroding, dispersible or dissolvable matrix systems, tablets and multiparticulates; and 3) coated matrix systems. Another class of controlled-release dosage forms consists of reservoir systems where release of the drug is modulated by a membrane, such as

25 capsules and coated tablets or multiparticulates. A third class consists of osmotic-based systems such as 1) coated bilayer tablets; 2) coated homogeneous tablet cores; 3) coated multiparticulates; and 4) osmotic capsules. A fourth class consists of swellable systems where drug is release by a swelling and then extrusion of the core components out through a passageway in a coating or surrounding shell or

30 outer layer.

The invention is further illustrated by the following examples, which are not to be taken as limiting.

Example 1

This example illustrates that organic acids have the ability to raise the solubility of the hydrochloride salt of sertraline. The acids were tested by dissolving the candidate acid in water and then stirring excess sertraline hydrochloride in the acid solution for at least 8 hours. The concentration of sertraline in the supernatant was then measured by HPLC analysis. The results of this test are shown in Table 1-1, below. Most of the acids listed in the table successfully raised the solubility of sertraline hydrochloride (normal solubility 2.5 mg/ml).

Table 1-1

Excipient	Approximate Excipient Concentration (mg/ml)	Sertraline Solubility (mg/ml)
D,L-malic acid	900	21
Citric acid	600	20
Erythorbic acid	400	19
Adipic acid	14	12
Maleic acid	700	6.4
L-aspartic acid	10	5.5
Tartaric acid	1400	5.5
L-glutamic acid	12	5.4
Fumaric acid	11	3.1
Tannic acid	2000	2.8
D,L-tyrosine	600	2.2

Preferred acids, based on the above-described test, are malic, citric, erythorbic, and adipic acids. Maleic, L-aspartic, tartaric, and L-glutamic acids also significantly improved sertraline hydrochloride solubility. Some controlled-release dosage forms with such acids in the core will perform better than those without such acids. This is particularly true for osmotic-based formulations that deliver a solution of drug.

Example 2

This example illustrates that organic acids have the ability to raise the solubility of the acetate salt of sertraline by a test method similar to that used for the hydrochloride salt described in Example 1. The solubilizing agent, its concentration, and resulting sertraline solubility are shown in Table 2-1 below. Based on these results, preferred acids to include in a dosage form where increased sertraline

acetate solubility is desired are ascorbic, erythorbic, citric, lactic, aspartic, glutamic, and aconitic acids.

Table 2-1

Excipient	Excipient Concentration (mg/ml)	Sertraline Solubility (mg/ml)
Ascorbic acid	400	>425
Erythorbic acid	400	>330
Citric acid	600	146
Lactic acid	213	>294
Aspartic acid	7	110
Glutamic acid	12	108
Aconitic acid	500	>92
Itaconic acid	150	72
Succinic acid	77	28
None	—	64

5

Example 3

- This example illustrates that organic acids and three calcium salts have the ability to raise the aqueous solubility of the lactate salt of sertraline using a method similar to that used for the hydrochloride salt described in Example 1. The solubilizing agent, its concentration in the aqueous test solution, and the sertraline lactate solubility in the test solution are listed in Table 3-1 below. Solubility of sertraline lactate in water is approximately 125 mg/ml. The data below show that eight organic acids effected sertraline lactate solubilities about the same as or higher than 125 mg/ml; adipic, erythorbic, itaconic, citric, aspartic, glutamic, histidine, and ascorbic. Also, a solution of a mixture of two of these acids also had high solubility; ascorbic and aspartic. Sertraline lactate solubility was also high in calcium salt solutions, either alone (calcium citrate) or mixed with ascorbic acid.

Table 3-1

Excipient	Excipient Concentration (mg/ml)	Sertraline Lactate Solubility (mg/ml)
Adipic acid	14	360
Erythorbic acid	400	>217
Itaconic acid	150	>202
Citric acid	600	162
Aspartic acid	7	>155
Glutamic acid	12	>125
Histidine	42	>116
Ascorbic/Aspartic	400/7	116
Ascorbic	400	102
Glycine	250	66
Aconitic acid	200	<59
Tartaric acid	1400	12
Fumaric acid	11	<9
Sorbic acid	3	<9
Calcium lactate/ Ascorbic acid	50/400	160
Calcium citrate	10	165
Calcium carbonate/ Ascorbic acid	50/400	176
None	—	125

Example 4

- 5 The lower solubility of the sertraline chloride salt and of all sertraline lactate and sertraline acetate salts in the presence of high chloride concentrations suggest that core formulations are preferred for which sertraline stays in solution that is, it does not precipitate or form a gel-like material when chloride is present. Certain organic acids and salts were found to inhibit precipitation or gelation of sertraline when
- 10 chloride is present via the following screening test. Sertraline lactate was dissolved in water either alone (as a control) or with a candidate solubilizing agent. Sodium chloride was then added (as a concentrated solution) and the result observed. An excipient was considered beneficial if the solution remained clear and fluid. The more chloride that could be added to an excipient solution with the solution remaining
- 15 clear, the more beneficial was the excipient. Table 4-1 below shows the results of this screening test, indicating that all the excipients tested increased sertraline concentration in the chloride solutions.

Table 4-1

Excipient	Excipient Concentration (mg/ml)	Concentration NaCl (mM)	Final Sertraline Concentration (mg/ml)	Observation After NaCl Addition
None	—	38	22	gel/precipitate
Ascorbic/Aspartic acids	400/7	152	162	solution
Aspartic acid	7	114	162	solution
	7	152	100	gel
Ascorbic acid	400	100	102	precipitate
Ascorbic acid/calcium lactate	400/50	150	165	solution
Ascorbic acid/calcium carbonate	400/50	150	170	slightly turbid
Citric acid/calcium lactate	600/50	150	162	solution
Histidine	42	150	110	slight precipitate

Example 5

5

Organic compounds (solubilizers) were screened for their ability to enhance the solubility of sertraline lactate in aqueous solutions with or without the presence of chloride. Excess sertraline lactate was added to an aqueous solution of the candidate solubilizer and, in most cases an organic acid. The organic acids were saturated in these solutions and the additional solubilizing agents were at the concentration shown in Table 5-1. The equilibrium sertraline solubility was measured. Then, sodium chloride was added to the saturated solution and the final sertraline concentration was measured. The results of these screening tests are summarized in Table 5-1.

10

Table 5-1

	Solubilizer	Solubilizer Concentration (mg/ml)	Organic Acid	Setraline Solubility (mg/ml)	NaCl Concentration (mM)	Setraline Concentration with NaCl (mg/ml)
1	None (control)	--	none	125	150	5
2	Monocaprylin	10	ascorbic	160	150	160
3	Triacetin	100	ascorbic	170	150	170
4	Monobutyrin	50	none	120	150	120
5	Diacetin	50	ascorbic	120	150	120
6	Imwitor [®] 312	10	ascorbic	120	150	120
7	Imwitor [®] 375	10	ascorbic	120	150	120
8	Imwitor [®] 742	50	none	120	150	120
9	Imwitor [®] 988	50	none	140	100	140
10	Triethyl citrate	50	ascorbic	160	150	160
11	Pluronic [®] L31	50	none	120	100	120
12	Cremophore [®] EL	50	ascorbic	120	150	120
13	Sucrose acetate isobutyrate	50	ascorbic	120*	150	120
14	Sodium capryl lactate	50	ascorbic	120	150	120
15	Sucrose monolaurate	50	none	150	150	150
16	Sodium lauryl lactate	50	ascorbic	120	150	120
17	Span 80	50	ascorbic	120	150	120

Example 6

- This example illustrates that solubilizers for sertraline also can increase the rate of dissolution of sertraline. The effect of a candidate excipient on sertraline
- 5 dissolution rate was determined by adding solid drug, the candidate solubilizing excipient, and, in some cases, other excipients such as an organic acid and an osmagent (such as a sugar) to a 1.8 ml centrifuge tube. The sample tubes were spun at 14K G for 5 minutes in a microcentrifuge to pack the powder. 150 μ l gastric
- 10 buffer was added to the packed powder and the samples were gently agitated, then spun at 14K G in a microcentrifuge for 2 minutes. The samples were then removed from the microcentrifuge and allowed to stand undisturbed until the solution was removed. The solution was removed from the samples after a total of 10 minutes after gastric buffer was added to the powder pack, and analyzed by HPLC to determine the sertraline concentration.
- 15 The dissolution rate (mg sertraline/ml-min) was calculated from the measured concentration of dissolved sertraline in the supernatant as a function of time over the first 10 minutes of dissolution. These dissolution rates and the excipient mixtures for which they were measured are summarized in Table 6-1 below. As shown, several excipient mixtures containing solubilizers significantly (about 3X or greater) increased
- 20 the dissolution rate of sertraline, compared with sertraline alone and compared with sertraline and ascorbic acid.

Table 6-1

Name	Candidate Excipient		Organic Acid Conc. (wt%)	Osmagent	Osmagent Conc. (wt%)	Other Excipient	Other Excipient Conc. (wt%)	Sertraline Salt Form Conc. (wt%)	Sertraline Dissolution Rate (mg/ml-min)
		Concentration (wt%)							
None		--	none	none	--	none	--	lactate 100	
None		--	ascorbic	lactose	20	none	--	lactate 14	3.5
Inwitor® 312		5.0	ascorbic	lactose	12.5	CaCO ₃	5	lactate 14	20.9
Lecithin		5.0	ascorbic	lactose	15	none	--	lactate 14	10
PEG 3550		5.0	ascorbic	lactose	15	none	--	lactate 14	9.3
Capmul® MCM		5.0	ascorbic	none	--	none	--	lactate 24	14.5
Capmul® MCM		4.7	none	lactose	17	CaCO ₃ Ca citrate	4.7 47	lactate 13.1	4.3
Inwitor® 191		5.0	ascorbic	lactose	12.5	CaCO ₃	1.0	lactate 14	8.0
Myverol® (18-99)		5.0	ascorbic	lactose	12.5	none	--	lactate 14	6.4
Span® 60		5.0	ascorbic	lactose	15	none	--	lactate 14	9.5
Ascorbyl palmitate		6.8	none	lactose	74.2	none	--	lactate 19	4.3

Methyl paraben/ propyl paraben/ propyl gallate Inwitor® 312	0.5/0.5/1.0	ascorbic	50.0	lactose	17.5	none	--	lactate 14	11.5
	6.8	aspartic	7402	none	--	none	--	lactate 19	5.3

Example 7

- This examples illustrates a method for making osmotic tablets comprising a tablet core containing sertraline with and without solubilizing agents surrounded by a semipermeable asymmetric membrane coating. In this example the benefit of incorporating solubilizers into a controlled-release formulation containing sertraline is demonstrated. Sertraline-hydrochloride was triturated by hand for 10 minutes with citric acid and microcrystalline cellulose (Avicel PH 102, FMC) using a 6 1/2 inch diameter mortar and pestle. Magnesium stearate was then blended in as a lubricant by stirring with a spatula for 60 seconds. The weight ratio of sertraline-hydrochloride to citric acid to microcrystalline cellulose to magnesium stearate was 8.5:63.8:23.7:4; with a total weight of 10 grams. The blended mixture was pressed into 470 mg tablets in a modified hydraulic jack (manufactured by Dayton) fitted with a pressure gauge and 3/8 inch concave punch under 2500 PSI pressure for 2 seconds. The dimensions of the resulting tablets were 3/8 inch in diameter and 1/4 inch thick. A semipermeable membrane coating (as described in U.S. Patent 5,612,059 was applied to these tablets using a LDCS-20 pan coater (Vector Corp.) at a spray rate of 20 grams per minute, an inlet temperature of 40°C and air flow of 40 cfm. The coating solution contained by weight 10% Cellulose acetate, (Eastman Chemical, CA398-10), 2.5% polyethylene glycol (BASF, PEG 3350), 15% water and 72.5% acetone. The coated tablets were dried 1 hour at 50°C before testing. After drying, the weight of applied coating material was 15.4% of the total weight. Additional osmotic delivery tablets were prepared by using essentially the same procedure for making the tablet cores and applying the asymmetric membrane coating to the cores described above. The composition of the cores and coating solution varied as shown in Table 7-1. Significant core compositional changes shown include: the sertraline salt form, the type and amount of solubilizer, and the type and amount of osmagent. The amount of binder (Avicel[®]) lubricant (magnesium stearate), and solubilizer were varied as necessary to obtain good tableting and wetting properties. These tablets all contained a sertraline dose of 50 mgA/tablet.

Table 7-1

Example No.	Core Composition										Coating Solution						
	Core Weight (mg)	Drug		Solubilizer Acid		Solubilizer		Osmogent		Mg St. wt %	Other	Polymer Type	Polymer wt %	PEG wt %	Water wt %	Coating Weight (dry wt %)	
		Salt Form	Wt %	Type	Wt %	Type	Wt %	Type	Wt %								
7a	470	chloride	12		none		none		lactose	66	2	none	CA	10	2.5	15	15.4
7b	470	lactate	14		none		none		lactose	65.4	1.33	none	EC	6	4	8	1
7c	470	lactate	14	aspartic	11		none		fructose	38	29.5	Ca Acetate	CA	10	2.5	15	11
7d	470	lactate	14	glutamic	10		MC	5	sucrose	50	15	none	EC	6	4	10	10.1
7e	470	lactate	14	aspartic	11		lm	5	fructose	36	27	2.5	Ca acetate	10	2.5	15	10.3
7f	470	lactate	14	glycine	25		lm	5	fructose	28.5	25	2.5	none	10	2.5	15	15.9
7g	470	lactate	14	aspartic	11		lm	5	fructose	36	27	2.5	Ca acetate	10	2.5	15	20
7h	470	lactate	14	aspartic	11		none		fructose	38	29.5	2.5	Ca acetate	10	2.5	15	10

IM = Imwitor® 312 CA = cellulose acetate 398-10 EC = Ethocel S-100
MC = monocaprylin Mg St = magnesium stearate
5 PEG = polyethylene glycol 3350 Myrj = Myrj® 52

The rates of release of sertraline from these formulations were determined testing the tablets in a USP Apparatus #2 with paddle stirring speed set at 100 rpm. The receptor solution used in the dissolution apparatus was 0.13M acetate buffer at pH 4.0 with 0.075M sodium chloride kept at 37°C. Samples of the receptor solution were taken at the times shown in Table 7-2. Analysis of sertraline released was determined by reverse-phase high-performance liquid chromatography (RP HPLC).

The results of release-rate tests performed using these procedures are listed in Table 7-2. The first two formulations listed, 7a and 7b show low release rates and are included as comparison examples. Both these formulations contain a sertraline salt (hydrochloride or lactate) and only lactose as the osmagent and no solubilizing excipients. The remaining formulations (7c-7h) listed in Table 7-2 all contain one or more solubilizing excipients and all demonstrate significantly higher release rates of sertraline compared with the formulations that do not contain solubilizers.

Table 7-2

Tablets of Example No	Fraction of Drug Released (%) At Specified Time						
	0 Hr	1 Hr	2 Hr	4 Hr	8 Hr	12 Hr	20 Hr
7a	0	0	0	0	0	0	0
7b	0	0	1	2	—	10 (17 hr)	12
7c	0	6	15	35	62	76	78
7d	0	0	0	4	19	28	44
7e	0	8	19	37	60	73	83
7f	0	0.7	6	17	37	54	78
7g	0	0.4	4	13	31	41	53
7h	0	8	18	38	56	64	66

What is claimed is:

1. A composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a solubilizing agent sufficient to produce a concentration of dissolved sertraline in a use environment containing chloride ions which is 1.5 times higher than the concentration effected by a comparative composition of matter identical thereto but for the inclusion of said solubilizing agent.
2. A composition of matter as defined in claim 1, wherein said use environment is the GI tract.
3. A composition of matter as defined in claim 1, wherein said use environment is an aqueous chloride ion-containing test medium.
4. A composition of matter as defined in claim 3, wherein said use environment is 0.075 M sodium chloride.
5. A composition of matter as defined in claim 1, which is an immediate release dosage form.
6. A composition of matter as defined in claim 1, which is a controlled release dosage form.
7. A composition of matter as defined in claim 1, wherein said solubilizing agent is selected from:
 - 1) organic acids and organic acid salts;
 - 2) partial glycerides;
 - 3) glycerides;
 - 4) glyceride derivatives;
 - 5) polyethylene glycol esters;
 - 6) polypropylene glycol esters;
 - 7) polyhydric alcohol esters;

- 8) polyoxyethylene ethers;
- 9) sorbitan esters;
- 10) polyoxyethylene sorbitan esters; and
- 11) carbonate salts.

5

8. A composition of matter as defined in claim 4, wherein the amount of said solubilizing agent is sufficient to maintain, for at least 2 hours, the concentration of dissolved sertraline at a level which is at least 1.5 times higher than the concentration of sertraline produced by a comparative composition of matter identical thereto but for the inclusion of said solubilizing agent.

10

9. A composition as defined in claim 1, wherein said solubilizing agent is selected from aspartic acid, glyceryl monocaprylate, glyceryl monolaurate, calcium acetate, ascorbic acid, citric acid, glutamic acid, and calcium carbonate.

15

10. A composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a solubilizing agent sufficient to produce and to maintain, for at least 2 hours in 0.075M sodium chloride, a concentration of dissolved sertraline which is at least 1.5 times higher than the concentration effected by a comparative composition of matter identical thereto but for the inclusion of said solubilizing agent.

20

11. A composition of matter as defined in claim 10, which is an immediate release dosage form.

25

12. A composition of matter as defined in claim 10, which is a controlled release dosage form.

13. A composition of matter as defined in claim 10, wherein said solubilizing agent is selected from:

30

- 1) organic acids and organic acid salts;
- 2) partial glycerides;

- 3) glycerides;
4) glyceride derivatives;
5) polyethylene glycol esters;
6) polypropylene glycol esters;
5 7) polyhydric alcohol esters;
8) polyoxyethylene ethers;
9) sorbitan esters;
10) polyoxyethylene sorbitan esters; and
11) carbonate salts.

10

14. A composition as defined in claim 10, wherein said solubilizing agent is selected from aspartic acid, glyceryl monocaprylate, glyceryl monolaurate, calcium acetate, ascorbic acid, citric acid, glutamic acid, and calcium carbonate.

15

15. A composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a solubilizing agent sufficient to effect, *in vivo*, a C_{max} and/or an AUC which is greater by at least 10% than the C_{max} and/or AUC effected by a comparative composition of matter identical thereto but for the inclusion of said solubilizing agent.

20

16. A composition as defined in claim 15, wherein said C_{max} and/or AUC effected by said solubilizing agent-containing composition is at least 15% higher than the corresponding C_{max} and/or AUC effected by said comparative composition.

25

17. A composition as defined in claim 16, wherein said C_{max} and/or AUC effected by said solubilizing agent-containing composition is at least 20% higher than the corresponding C_{max} and/or AUC effected by said comparative composition.

30

18. A composition of matter as defined in claim 15, which is an immediate release dosage form.

19. A composition of matter as defined in claim 15, which is a controlled release dosage form.

20. A composition of matter as defined in claim 15, wherein said
- 5 solubilizing agent is selected from:
- 1) organic acids and organic acid salts;
 - 2) partial glycerides;
 - 3) glycerides;
 - 4) glyceride derivatives;
 - 10 5) polyethylene glycol esters;
 - 6) polypropylene glycol esters;
 - 7) polyhydric alcohol esters;
 - 8) polyoxyethylene ethers;
 - 9) sorbitan esters;
 - 15 10) polyoxyethylene sorbitan esters;
 - 11) carbonate salts.

21. A composition of matter as defined in claim 15, wherein said
- solubilizing agent is selected from aspartic acid, glyceryl monocaprylate, glyceryl
- 20 monolaurate, calcium acetate, ascorbic acid, citric acid, glutamic acid, and calcium carbonate.

22. A method of increasing the solubility of sertraline in an aqueous
- chloride ion-containing use environment, comprising administering said sertraline to
- 25 said use environment in a composition of matter additionally comprising a solubilizing agent.

23. A method as defined in claim 22, wherein the concentration of
- dissolved sertraline in said use environment also containing said solubilizer is at least
- 30 1.5-fold higher than the concentration of sertraline effected by a comparative composition identical to said solubilizing agent-containing composition except for the inclusion of said solubilizing agent.

24. A method as defined in claim 22, wherein said use environment is the GI tract.

5 25. A method as defined in claim 22, wherein said use environment is an aqueous chloride ion-containing test medium.

26. A method as defined in claim 25, wherein said medium is 0.075 M sodium chloride.

10

27. A method as defined in claim 22, wherein said composition of matter is in the form of an immediate release dosage form.

15 28. A method as defined in claim 22, wherein said composition of matter is in the form of a controlled release dosage form.

29. A method as defined in claim 22, wherein said solubilizing agent is selected from:

- 20
- 1) organic acids and organic acid salts;
 - 2) partial glycerides;
 - 3) glycerides;
 - 4) glyceride derivatives;
 - 5) polyethylene glycol esters;
 - 6) polypropylene glycol esters;

25

 - 7) polyhydric alcohol esters;
 - 8) polyoxyethylene ethers;
 - 9) sorbitan esters; and
 - 10) polyoxyethylene sorbitan esters.
 - 11) carbonate salts

Please type a plus sign (+) inside this box →



**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration
submitted
with Initial
Filing

☐ Declaration
Submitted after Initial
Filing (surcharge
37 CFR 1.16 (e)
required)

Attorney Docket Number	PC9835AJTJ
First Named Inventor	Dwayne Thomas FRIESEN
COMPLETE IF KNOWN	
Application Number	Not yet assigned
Filing Date	Filed herewith
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SOLUBILIZED SERTRALINE COMPOSITIONS

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 06/15/1998 as United States Application Number or PCT International

Application Number PCT/IB98/00933 which was amended under PCT Rule 66.3 during

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B sheet attached hereto.
60/051,413	07/01/1997	

EXPRESS MAIL NO. 25248206579US [Page 1 of 3]

Please type a plus sign (+) inside this box →

+

DECLARATION ---- Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 U.S.C. 1.56, which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Parent Application Number or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/IB98/00933	June 15, 1998	

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☐ Customer Number ☐ Place Customer Number Bar Code Label here

☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Peter C. Richardson	27,526	Mark Dryer	28,775
Allen J. Spiegel	25,749	Lawrence C. Akers	28,587
Paul H. Ginsburg	28,718	A. Dean Olson	31,185
J. Trevor Lumb	28,567	Mervin E. Brokke	32,723
James T. Jones	30,561	Valerie M. Fedowich	33,688
Gregg C. Benson	30,977	Bryan C. Zielinski	34,462
Robert F. Shayka	31,304	Robert T. Ronau	36,257
Grover F. Fuller Jr.	31,760	B. Timothy Creagan	39,156
Karen DeBenedictis	32,977	Alan L. Koller	37,371
Lorraine B. Ling	35,251	Jolene W. Appleman	35,428
Garth Butterfield	36,997	Kristina L. Konstas	37,864
Carl J. Goddard	39,203	Seth H. Jacobs	32,140
Raymond M. Speer	26,810	Martha A. Gammill	31,820
Jennifer A. Kispert	40,049	Gregory P. Raymer	36,647
Jacob M. Levine	32,509	E. Victor Donahue	35,492
Israel Nissenbaum	27,582	Roy F. Waldron	42,208

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to:


☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below

Name	Gregg C. Benson				
Address	Pfizer Inc, Bldg. 118S, 3 rd Floor				
Address	Eastern Point Road				
City	Groton	State	CT	Zip Code	06340
Country	United States Of America	Telephone	1-(860)-441-4901	Fax	1-(860)-441-5221

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])		Family Name or Surname			
Dwayne Thomas		FRIESEN			
Inventor's Signature					Date Sept. 3, 99
Residence: City	Bend	State	OR	Country	US
Post Office Address	60779 Currant Way				
Post Office Address					
City	Bend	State	OR	Zip	97702
Country	US				

☒ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

09380825-090709

Please type a plus sign (+) inside this box →

+

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Scott Max				HERBIG			
Inventor's Signature	<i>Scott Max Herbig</i>					Date	8/31/99
Residence: City	East Lyme	State	CT	Country	US	Citizenship	US
Post Office Address 39 Heritage Road							
Post Office Address							
City	East Lyme	State	CT	Zip	06333	Country	US

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Ravi Mysore				SHANKAR			
Inventor's Signature	<i>Ravi Mysore Shankar</i>					Date	9/3/99
Residence: City	Groton	State	CT	Country	US	Citizenship	IN
Post Office Address 600 Meridian Street, Extension No. 816							
Post Office Address							
City	Groton	State	CT	Zip	06340	Country	US

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
James Blair				WEST			
Inventor's Signature	<i>James Blair</i>					Date	9/3/99
Residence: City	Bend	State	OR	Country	US	Citizenship	US
Post Office Address 5327 Whitewing Court							
Post Office Address							
City	Bend	State	OR	Zip	97701	Country	US

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	